Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.
about
Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancerOsimertinib making a breakthrough in lung cancer targeted therapyAntitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancerIs it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis.Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: Long-term follow-up resultsOne reporter for in-cell activity profiling of majority of protein kinase oncogenes.Is epidermal growth factor receptor tyrosine kinase inhibitor in combination with cytotoxic chemotherapy a better treatment option for patients with EGFR-mutated non-small-cell lung cancer?Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients.AZD9291-induced Acute Interstitial Lung Disease.Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients.Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.[Treatment of Advanced Squamous Cell Lung Cancer].Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients.An in Vitro Assay of hERG K + Channel Potency for a New EGFR Inhibitor FHND004.
P2860
Q28075704-E368B58F-CA34-4E12-B90C-BA83DBF19596Q28079689-BA266EFB-50CB-4C5F-991E-F9B28FD91C41Q33744196-865E92AF-6430-4433-99BC-932BF38E25F2Q35858399-A58F0562-4176-4BEF-A107-C01ED6F651FEQ37225463-6AA6633D-6C2B-400C-98E0-E90711ADB2A6Q37468081-BCC1D315-2509-4AEE-8C98-25DD42F6E74EQ37594039-08439522-1EE1-4D7C-80D6-E57D2EB73F73Q37643703-3C888E0C-CDE7-4EE7-B4F7-24F4E019CD5DQ38549723-22637663-653A-4D2A-B3FD-A42C2B3878F6Q42279529-0F30F040-F6B8-484E-833C-C4AAA8E61F67Q42700419-D2329DB9-5FF3-4C12-8895-8935F6C1654AQ42835050-9DFAE5D6-1811-49AC-9C39-02C3D8C332D6Q52611428-E0B7D7F8-93A0-40D9-8C52-2CEB33DB5EEAQ52803546-0F423F69-8052-4DEC-9172-93E686A88323Q53394177-696BC76C-9CA1-487F-B3DE-576EC47EBC7BQ54169604-1B88E331-80BC-48F0-8FA2-C6EB4F674A14Q55080681-70B08EAE-B298-47FA-8034-482C2B5FABEFQ55175160-B438E385-F1B9-4164-9D36-3468F03B284A
P2860
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Clinical activity of the mutan ...... nt non-small cell lung cancer.
@en
Clinical activity of the mutan ...... nt non-small cell lung cancer.
@nl
type
label
Clinical activity of the mutan ...... nt non-small cell lung cancer.
@en
Clinical activity of the mutan ...... nt non-small cell lung cancer.
@nl
prefLabel
Clinical activity of the mutan ...... nt non-small cell lung cancer.
@en
Clinical activity of the mutan ...... nt non-small cell lung cancer.
@nl
P2860
P1476
Clinical activity of the mutan ...... nt non-small cell lung cancer.
@en
P2093
Caicun Zhou
P2860
P304
P356
10.3978/J.ISSN.2218-6751.2014.08.02
P577
2014-12-01T00:00:00Z